AG Session: The Department of Justice under my watch is committed to transparency and the rule of law

DOJ to release Fast and Furious details Holder kept hidden

http://www.wnd.com/2018/03/doj-to-release-fast-and-furious-details-holder-kept-hidden/

Attorney General Jeff Sessions announced Wednesday that documents related to the failed Fast and Furious federal gun-running program that former Attorney General Eric Holder kept hidden are going to be released.

Katie Pavlich at Townhall noted Holder was voted “in civil and criminal contempt of Congress” for his actions.

Obama invoked executive privilege in June 2012 to prevent the release of the documents after the courts had said they could be publicized.

The DOJ said Wednesday the documents will be turned over to the House Oversight Committee.

“The Department of Justice under my watch is committed to transparency and the rule of law.

This settlement agreement is an important step to make sure that the public finally receives all the facts related to Operation Fast and Furious,” Sessions announced.

The release is part of the settlement of a federal case that stemmed from the Obama administration’s refusal to share the information with Congress.

The Fast and Furious plan was to allow highly specialized weapons to be sold so they could be traced to Mexican drug-cartel leaders.

 

But the Obama administration lost track of many of the weapons, and some were used in murders, including the slaying of Border Patrol Agent Brian Terry.

In a Fox News interview, Terry’s brother called on the Trump administration to reopen the investigation into the operation and to release previously withheld documents.

“We need to find out the truth, exactly what happened, how it happened, why it happened. We need Mr. Trump, President Trump, to unseal the documents, reverse executive privilege so that we know what happened, and that we can hold the people accountable that are responsible,” Kent Terry said.

Brian Terry died at the hands of Mexican cartel members in December 2010. They were carrying guns illegally trafficked by ATF to Mexico through the Fast and Furious program.

The operation trafficked “thousands of AK-47s,” as well as .50 caliber rifles.

WND reported two years ago that the failed sting operation was linked to an additional 69 deaths, including a massacre in which 22 died, in addition to the 200 deaths in Mexico alone that were reported in previous years.

I made this post… not because of the context of it..but.. because AG Session keeps talking about “the rule of law” under his watch. There a increasing number of insurance companies, PBM’s, healthcare corporations that are putting things in place that will end up with discriminating against the care that those in the chronic pain community will receive.

How to File an ADA Complaint with the U.S. Department of Justice

If AG Session  is so committed to “the rule of law” then this agency under the Dept of Justice should start taking – and acting on – complaints of discrimination from the chronic pain community SERIOUSLY..  Doesn’t make any difference if it is the DEA, CDC, FDA, CMS, HHS, state legislatures, insurance companies, PBM’s, healthcare corporations if his DOJ is going to enforce all laws equally… then let’s see if he will keep his word. or he is just using this “sound bite” to make  point about a particular issue that he feels warrants to be enforced ?

To date, most of what I have heard is that this part of DOJ … doesn’t have the resources…  Perhaps as more and more chronic painers file their complaints and take those “not enough resources” to the media. Our government can spend 81 billion/yr to fight the war on drugs… but… doesn’t have the resources to protect millions and millions of citizens who are being discriminated against by our own government ?

 

What the JAMA Opioid Study Didn’t Find

www.painnewsnetwork.org/stories/2018/3/10/what-the-krebs-opioid-study-didnt-find

A recent opioid study published in the Journal Of the American Medical Association (JAMA)  evaluated pain management in patients with hip and knee osteoarthritis and low back pain.

The study by VA researcher Erin Krebs, MD, and colleagues found that “treatment with opioids was not superior to treatment with nonopioid medications for improving pain-related function over 12 months.”  

That finding was widely and erroneously reported in the news media as meaning that opioids are ineffective for all types of chronic pain.

bigstock-Chronic-Pain--Medical-Concept-89339426.jpg

But the most fascinating result of the study – the one not being reported — is what wasn’t found. The 108 people in the study who took opioids for a year did not develop signs of opioid misuse, abuse or addiction, and did not develop opioid-induced hyperalgesia – a heightened sensitivity to pain.

And no one died of an overdose.

This is significant because it runs counter to commonly held beliefs in the medical profession about the risks of prescription opioids. Here are a few recent examples:

“Opioids are very addictive and their effectiveness wanes as people habituate to the medication,” Carl Noe, MD, director of a pain clinic at the University of Texas Medical Center wrote in an op/ed in The Texas Tribune.

Don Teater, MD, a family physician in North Carolina, also believes that people on long-term opioid therapy experience dose escalation, which leads to hyperalgesia. “Opioids cause permanent brain changes,” Teater told USA Today.

Krebs herself has made similar comments. “Within a few weeks or months of taking an opioid on a daily basis, your body gets used to that level of opioid, and you need more and more to get the same level of effect,” she told NPR.

But the Krebs study didn’t see any of that happen.

Krebs and colleagues closely monitored the 108 people in the opioid arm of the study, using “multiple approaches to evaluate for potential misuse, including medical record surveillance for evidence of ‘doctor-shopping’ (seeking medication from multiple physicians), diversion, substance use disorder, or death.” They also had participants complete the “Addiction Behavior Checklist” and assessed their alcohol and drug use with surveys and screening tools.

What did Krebs find in the opioid group after 12 months of treatment?

“No deaths, ‘doctor-shopping,’ diversion, or opioid use disorder diagnoses were detected,” she reported. “There were no significant differences in adverse outcomes or potential misuse measures.”

Health-related quality of life and mental health in the opioid group did not significantly differ from the non-opioid group – and their anxiety levels actually improved.  

These are observational findings in the study. They were not a part of what Krebs and colleagues were specifically trying to measure. As the study notes: “This trial did not have sufficient statistical power to estimate rates of death, opioid use disorder, or other serious harms associated with prescribed opioids.”

 ERIN KREBS, MD

ERIN KREBS, MD

But they are valuable observations. They note what didn’t happen in the study. Over 100 people were put on opioid therapy for a year, and none of them showed any signs of dose escalation or opioid-induced hyperalgesia, or any evidence of opioid misuse, abuse or addiction.

Krebs told the Minneapolis Star Tribune that this “could reflect the fact that the study did not enroll patients with addiction histories, and because the VA provided close supervision to all participants during the yearlong study.”

In other words, Krebs and colleagues used an opioid prescribing protocol that achieved an admirable level of patient safety. Their approach is similar to what many pain management practices currently pursue and what the CDC and various state guidelines recommend: Risk assessment before initial prescribing and careful monitoring over time.

The Krebs study provides rare and detailed observations of what happens when people are put on long-term opioid therapy. A lot of what is claimed about dose escalation, opioid-induced hyperalgesia, and misuse or abuse didn’t happen at all.

This outcome demonstrates that long-term opioid therapy can be safe and effective, and may be useful in treating other chronic conditions, from intractable neuropathies to painful genetic disorders. That’s worth reporting too, isn’t it?

 

 

 

Roger Chriss.jpg

Roger Chriss lives with Ehlers Danlos syndrome and is a proud member of the Ehlers-Danlos Society. Roger is a technical consultant in Washington state, where he specializes in mathematics and research.

The information in this column should not be considered as professional medical advice, diagnosis or treatment. It is for informational purposes only and represents the author’s opinions alone. It does not inherently express or reflect the views, opinions and/or positions of Pain News Network.

DON’T PUNISH PAIN RALLY

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Dear Friends and Family,

I am writing you to invite you to an event in Arizona.  Many of you know that I am an advocate on behalf of the chronic pain community.  This year, on Saturday April 7, one of our advocacy groups is planning a nationwide rally called Don’t Punish Pain.  The false information we are being fed by the media is fueling the rapid rise of overdose deaths from illegal drugs, primarily imported fentanyl (not rx fentanyl) and heroin.

In its misguided and ignorant attempt to counter what it calls the Opioid Epidemic (which it isn’t; it’s an illegal drug crisis), the government is continually stripping away the civil rights of pain patients simply because of the type of medication they need.  The result of this is more death; once a patient has been abandoned by his/her physician and cannot get help, they are left with 3 choices:  to suffer a bedridden life to an early death from pain complications, to turn to street drugs, or to commit suicide.  The attached chart will show you the results.

In spite of these useless, punitive, Draconian measures, overdose deaths are going UP all across the country.  Addicts aren’t being “saved,” but these restrictive policies are torturing pain patients who were compliant and stable in their treatment.  No one is immune; these guidelines and restrictions are affecting ANYONE in pain – and that includes cancer victims, post-operative patients, as well as palliative care and hospice patients.  Our veterans are being hit the hardest.

I am inviting you all to the Don’t Punish Pain rally of your choice. I’m attaching a document that shows which states are participating so far (we have 30), and which states still need a spokesperson.  I am the spokesperson for Arizona, so I am also attaching Arizona’s event flier.  I am also adding a form letter you can use for legislators, doctors and medical personnel, and for the media.  Doctors are another target of this opioid crackdown: they are being raided by the DEA, arrested, and attacked without cause, which are among the biggest reasons they stop prescribing life-saving medication to patients.

I am also inviting you to participate in any way you can.  This is not a march or a fund-raiser; this is a rally to bring awareness to what this crackdown on opioid prescribing is really doing to our country.  Each of us, if not already in chronic pain, is just one motor vehicle accident, one illness, one surgery away from a lifetime of chronic pain.  And while there are other therapies for pain, many are dangerous, most are not covered by insurance, and no one has developed a true replacement for opioid medication.  The rug was jerked out from under us without anything in place to catch us when our doctors’ practices are closed down by the DEA, or our doctors kick us to the curb on trumped-up charges, even to the extent of lying about the results of a urine test.

You can help by:

Spreading the word.  You can do this with letters, phone calls, social media like Facebook and Twitter, and personal emails (like this one).  Print and share the flier appropriate to your state (or states, if you like).  Take the fliers with you wherever you go, and ask permission for them to be posted.

Attending a rally of your choice.  Numbers are important, and we are also in need of able-bodied people for support.  Please note that while the nationwide rallies are being held at 12 noon EST, the Arizona rally will be at 10:00am (I forgot to account for daylight savings time).  We need your presence.

From the attached list of states, if you have friends in unrepresented states, please share this with them for encouragement.  Hopefully, someone in each of these states will be willing to step forward to lead as a spokesperson.

Please pray for me, my family, and my health.  I’m fighting chronic illness as well as chronic pain, and would dearly love your prayers for wisdom, clarity, and physical strength to see this through.  I am very blessed to have Pat at my side, helping me.

Thank you for taking the time to read this rather long letter.  If for any reason you do not want to be on this mailing list, please let me know.  I don’t want to clog your inbox with unwanted emails.

Thank you all,

Lauri

 

 

Nondiscrimination Standards Under ACA Section 1557: Now Is the Time to Act

https://www.ebglaw.com/news/nondiscrimination-standards-under-aca-section-1557-now-is-the-time-to-act/

Health Care and Life Sciences Client Alert September 15, 2016

Epstein Becker Green Health Care and Life Sciences Client AlertHealth insurers and group health plan sponsors must closely review the final rule titled “Nondiscrimination in Health Programs and Activities” (“Final Rule”) implementing Section 1557 of the Affordable Care Act (“ACA”) that was published by the U.S. Department of Health and Human Services (“HHS”) on May 18, 2016.[1] Section 1557 prohibits discrimination on the basis of race, color, national origin, sex, age, or disability in certain health programs and activities. To address issues of discrimination in the health programs and activities of certain “Covered Entities” (defined below), the Final Rule clarifies and codifies existing nondiscrimination requirements and sets forth new standards to implement Section 1557, particularly with respect to the prohibition of discrimination on the basis of sex.

The Final Rule became effective on July 18, 2016; however, for those insurance issuers or group health plans that must alter their plan benefit designs based on the Final Rule, the effective date is the first day of the first plan or policy year on or after January 1, 2017. Regardless of the date and mechanism through which the Final Rule applies to you, now is the time to ensure that you understand the rule’s requirements and implement needed policy or operational changes.

Key Implementation Elements of the Final Rule

Who: A health program or activity, any part of which receives federal financial assistance, and any program or activity administered by an executive agency or an entity established under Title I of the Affordable Care Act

What: An individual may not be excluded from participation in, denied the benefits of, or otherwise subjected to discrimination on the basis of race, color, national origin, sex, age, or disability in, certain health programs and activities

When: Effective July 18, 2016, unless changes to health insurance or group health plan benefit design (including covered benefits, benefits limitations or restrictions, and cost-sharing mechanisms, such as coinsurance, copayments, and deductibles) are required—in which case, provisions will apply on the first day of the first plan year (or policy year in the individual market) beginning on or after January 1, 2017

Definitions

HHS, through such agencies as the Health Resources and Services Administration (“HRSA”), the Substance Abuse and Mental Health Services Administration (“SAMHSA”), the Centers for Disease Control and Prevention (“CDC”), and the Centers for Medicare & Medicaid Services (“CMS”), provides federal financial assistance via various mechanisms to health programs and activities of local governments, state governments, and the private sector.

“Federal financial assistance” includes grants, loans, subsidies, contracts of insurance, and other types of assistance. Such assistance also includes premium tax credits and advance payments of premium tax credits and cost-sharing reductions for health insurance coverage purchased through the Health Insurance Marketplaces.[2]

“Covered Entities” that are subject to the non-discrimination provisions in the Final Rule include:

  • Entities receiving federal financial assistance through their participation in Medicare (excluding Medicare Part B[3]) or Medicaid—for example:
    • short-term, rehabilitation, psychiatric, and long-term hospitals
    • facility-based and freestanding skilled nursing facilities/nursing facilities
    • home health agencies
    • physical therapy/speech pathology programs
    • end-stage renal disease dialysis centers
    • intermediate care facilities for individuals with intellectual disabilities
    • rural health clinics
    • independent practice physical therapy
    • comprehensive outpatient rehabilitation facilities
    • ambulatory surgical centers
    • hospices
    • organ procurement organizations
    • community mental health centers
    • Federally Qualified Health Centers
  • Hospital-based, office-based, or freestanding laboratories that receive federal financial assistance through Medicaid payments for covered laboratory tests
  • Community health centers receiving federal financial assistance through grant awards from HRSA
  • Health-related schools in the United States and other health education entities receiving federal financial assistance through grant awards to support health professional training programs that include oral health, behavioral health, medicine, geriatric, and physician’s assistant programs
  • State Medicaid agencies receiving federal financial assistance from CMS to operate the Medicaid Program, the Children’s Health Insurance Program (“CHIP”), and the Basic Health Program
  • State public health agencies receiving federal financial assistance from CDC, SAMHSA, and other HHS components
  • Health Insurance Marketplaces established under Title I of the ACA (including 17 State-Based Marketplaces and 34 Federally Facilitated Marketplaces)
  • Qualified health plan issuers receiving federal financial assistance through advance payments of premium tax credits and cost-sharing reductions (which include the health insurance issuers in the Federally Facilitated Marketplaces receiving federal financial assistance through advance payments of premium tax credits and cost-sharing reductions and issuers operating in the State-Based Marketplaces)
  • Physicians receiving federal financial assistance through Medicaid payments, “meaningful use” payments,[4] and other sources

The term ‘‘health program or activity’’ means “the provision or administration of health-related services, health-related insurance coverage, or other health-related coverage, and the provision of assistance to individuals in obtaining health-related services or health-related insurance coverage.”[5] For a Covered Entity that is principally engaged in providing or administering health-related services, health-related insurance coverage, or other health-related coverage, all of its operations are considered part of the health program or activity, including the provision of an employee health benefit program or wellness program to its employees.[6] Accordingly, if any part of a health care entity receives federal financial assistance, then all of its programs and activities are subject to the non-discrimination provisions in the Final Rule. However, the Final Rule does not apply to actions against a Covered Entity’s own employees, including actions related to hiring, firing, promotion, or terms and conditions of employment.

Application of the Nondiscrimination Provisions

The core objective of Section 1557 is to prohibit discrimination in “any health program or activity” on the grounds prohibited under Title VI of the Civil Rights Act of 1964[7] (race, color, or national origin), Title IX of the Education Amendments of 1972[8] (sex), the Age Discrimination Act of 1975[9] (age), and Section 504 of the Rehabilitation Act of 1973[10] (disability). The Final Rule is not intended to apply a lesser standard for the protection of individuals from discrimination than the standards and regulations already applied under these laws. Further, nothing in the Final Rule is intended to be interpreted to invalidate or limit the existing rights, remedies, procedures, or legal standards available to individuals aggrieved under other federal civil rights laws or to supersede state or local laws that provide greater or equal protection against discrimination on the basis of race, color, national origin, sex, age, or disability. The HHS Office of Civil Rights (“OCR”), the agency responsible for enforcing Section 1557, concludes that the regulations promulgated in the Final Rule preempt state law only where the exercise of state authority directly conflicts with or prevents the application of the Final Rule.

HHS did not include a blanket religious exemption in the Final Rule; however, the Final Rule includes a provision noting that, insofar as the application of any requirement under the rule would violate applicable federal statutory protections for religious freedom and conscience, such application would not be required.[11] Further, HHS allows for sex-specific health programs or activities, but only where the Covered Entity can demonstrate an exceedingly persuasive justification (i.e., that the sex-specific program is substantially related to the achievement of an important health-related or scientific objective).[12]

HHS establishes numerous requirements for Covered Entities under the Final Rule. For example, a Covered Entity:

  • must take reasonable steps to provide meaningful access to each individual with limited English proficiency;
  • must take appropriate steps to ensure that communications with individuals with disabilities are as effective as communications with others in health programs and activities;
  • if covered by the 2010 Americans with Disabilities Act (“ADA”) Standards for Accessible Design prior to July 18, 2016, must comply with those standards for new construction or alterations by July 18, 2016, and compliance with the Uniform Federal Accessibility Standards will be deemed compliance with the Final Rule only if construction or alteration was commenced before July 18, 2016, and the facility or part of the facility was not covered by standards under the ADA;
  • must ensure that its health programs or activities provided through electronic and information technology are accessible to individuals with disabilities, unless doing so would result in undue financial and administrative burdens or a fundamental alteration in the nature of the health programs or activities;
  • must provide individuals equal access to its health programs or activities without discrimination on the basis of sex and must treat individuals consistent with their gender identity;
  • must not discriminate on the basis of race, color, national origin, sex, age, or disability when providing or administering health-related insurance or other health-related coverage;
  • will be liable for violations of the Final Rule in any employee health benefit program that it provides to its employees and/or their dependents; and
  • must not exclude from participation in, deny the benefits of, or otherwise discriminate against an individual or entity in, its health programs or activities on the basis of the race, color, national origin, sex, age, or disability of an individual with whom the individual or entity is known or believed to have a relationship or association.[13]

Actions That Covered Entities Must Take to Comply with the Final Rule

Each entity applying for federal financial assistance, each issuer seeking certification to participate in a Health Insurance Marketplace, and each state seeking approval to operate a State-Based Marketplace is required to submit an assurance that its health programs and activities will be operated in compliance with Section 1557.[14]

Each Covered Entity that employs 15 or more persons must designate at least one employee to coordinate compliance with the requirements of the Final Rule.[15] A Covered Entity that has already designated a responsible employee pursuant to the regulations implementing Section 504 or Title IX may use that individual to coordinate its efforts to comply with Section 1557.

Further, a Covered Entity that employs 15 or more persons must adopt a grievance procedure that incorporates appropriate due process standards and allows for the prompt and equitable resolution of complaints concerning actions prohibited by Section 1557.[16] HHS clarifies that an individual does not have to exhaust a Covered Entity’s grievance procedure prior to filing a Section 1557 complaint. Additionally, HHS clarifies that a Covered Entity that already has a grievance procedure addressing claims of disability discrimination that meets the standards established under the Section 504 regulation may use that procedure to address disability claims under Section 1557. A Covered Entity may use that procedure to address all other Section 1557 claims, provided that the Covered Entity modifies the procedure to apply to race, color, national origin, sex, and age discrimination claims. HHS provides an example of how to structure a grievance procedure in Appendix C of the Final Rule.[17]

A Covered Entity must take appropriate initial and continuing steps to notify beneficiaries, enrollees, applicants, or members of the public of individuals’ rights under Section 1557 and of Covered Entities’ nondiscrimination obligations with respect to their health programs and activities.[18] Specifically, a Covered Entity’s notice must include the following statements and information:

  • The Covered Entity does not discriminate on the basis of race, color, national origin, sex, age, or disability
  • The Covered Entity provides appropriate auxiliary aids and services, free of charge and in a timely manner, to individuals with disabilities
  • The Covered Entity provides language assistance services, free of charge and in a timely manner, to individuals with limited English proficiency
  • How an individual can access such aids and services referenced above
  • The contact information for the responsible employee coordinating compliance with Section 1557 (when required)
  • The availability of a grievance procedure (when required), and how to file a grievance
  • How an individual can file a discrimination complaint with HHS

This notice must be posted in significant publications and communications, in conspicuous physical locations, and on the Covered Entity’s website by October 16, 2016 (90 days from the effective date of the Final Rule). HHS provides a sample notice and non-discrimination statement in Appendix A of the Final Rule.[19] Covered Entities may use the sample notice or they may develop their own. Covered Entities are encouraged, but not required, to post the notice in one or more of the most prevalent non-English languages frequently encountered in their geographic service areas. Further, Covered Entities may combine the required content of the notice with the content of other required notices, as long as the combined notice clearly informs individuals of their civil rights under Section 1557. However, a Covered Entity’s compliance with the notification requirements in the Final Rule does not constitute compliance with the notice requirements of other federal civil rights laws, such as Title IX and Section 504.

Covered Entities must also post by October 16, 2016, taglines in at least the top 15 languages spoken by individuals with limited English proficiency in the state or states where the Covered Entity operates.[20] HHS provides a sample tagline in Appendix B of the Final Rule.[21] Covered Entities may develop their own taglines, and they may choose to include taglines in more than 15 languages. Further, for significant publications and significant communications that are small-sized, Covered Entities must include the non-discrimination statement (in lieu of the full notice) and taglines in at least the top two languages spoken by individuals with limited English proficiency in the relevant state or states. OCR has posted translated resources in 65 languages, including a notice of nondiscrimination, a statement of nondiscrimination, and taglines, on its website for Covered Entities to use.[22]

A recipient of federal financial assistance or State-Based Marketplace that has been found to have discriminated on any of the bases prohibited by Section 1557 will be required to take remedial action to overcome the effects of that discrimination.[23] Further, a Covered Entity may take voluntary action in the absence of a finding of discrimination to overcome the effects of conditions that result or resulted in limited participation by persons based on race, color, national origin, sex, age, or disability.[24]

Equal Program Access on the Basis of Sex

The Final Rule requires Covered Entities to provide “equal access to its health programs or activities without discrimination on the basis of sex.”[25] The Final Rule uses the same definition for “on the basis of sex” as the proposed rule, which was released by HHS on September 8, 2015 (“Proposed Rule”).[26] Specifically, this term “includes, but is not limited to, discrimination on the basis of pregnancy, false pregnancy, termination of pregnancy, or recovery therefrom, childbirth or related medical conditions, sex stereotyping, and gender identity.”[27]

Sex Stereotyping

OCR continues to rely upon the U.S. Supreme Court’s holding in Price Waterhouse v. Hopkins[28] to support its inclusion of sex stereotyping in the definition of “on the basis of sex.” In the Final Rule, OCR clarified that sex stereotypes can be based on expectations about gender roles.   

Sexual Orientation

Under the Final Rule, OCR will evaluate complaints alleging sex discrimination related to an individual’s sexual orientation to determine whether the complaints can be addressed under Section 1557. In explaining this decision, OCR noted that it received comments both requesting OCR to explicitly state that discrimination on the basis of sex includes discrimination based on sexual orientation and, conversely, asserting that OCR does not have such authority to include sexual orientation because no federal appellate court has interpreted Title IX or Title VII to protect a same-sex relationship.

While acknowledging that no federal appellate court has concluded that federal laws prohibiting sex discrimination include a prohibition on sexual orientation discrimination, OCR noted that some recent court decisions have found that discrimination relating to an individual’s sexual orientation is prohibited because it constitutes discrimination on the basis of sex stereotyping.

As such, OCR concluded that “Section 1557’s prohibition of discrimination on the basis of sex includes, at a minimum, sex discrimination related to an individual’s sexual orientation where the evidence establishes that the discrimination is based on gender stereotypes.”[29] However, OCR did not say that discrimination on the basis of an individual’s sexual orientation alone is a form of discrimination under Section 1557. Covered Entities should pay close attention for legal developments as this area of unsettled law is ripe for litigation.

Gender Identity

Like the Proposed Rule, the Final Rule also requires Covered Entities to “treat individuals consistent with their gender identity.”[30] OCR defines “gender identity” to mean an individual’s internal sense of gender, which may be different than the sex assigned at birth. In response to comments about potential ambiguity regarding non-binary gender identities, OCR revised the Proposed Rule’s definition of “gender identity” to include the clause “which may be male, female, neither, or a combination of male and female.”

The Final Rule also clarifies that the term “gender identity” encompasses “gender expression” and “transgender status.” OCR noted that this is consistent with the position taken by some courts and federal agencies; therefore, these types of discrimination are prohibited under the Final Rule.

Gender Discrimination in Health-Related Insurance and Other Health-Related Coverage

The Final Rule adopts Section 92.207 of the Proposed Rule—which prohibits a Covered Entity from discrimination on the basis of race, color, national origin, sex, age, or disability—without substantive modification. This section also lists specific prohibited practices, including implementing a categorical coverage exclusion or limitation for all health services related to gender transition and denying or limiting coverage for a transgender individuals for any health services that are ordinarily available to individuals of one sex because the person’s sex assigned at birth is different from the one for which such health services are ordinarily available.

OCR refused to provide examples of discriminatory benefit designs. Instead, OCR will analyze “whether a design feature is discriminatory on a case-by-case basis” using the “facts and circumstances of a given scenario.”[31] OCR did acknowledge that Covered Entities have discretion in developing benefit designs and that the Final Rule “does not prevent covered entities from utilizing reasonable medical management techniques; nor does it require covered entities to cover any particular procedure or treatment.”[32] Specifically, OCR changed Section 92.101 to provide that sex-specific health programs or activities are allowable only where the Covered Entity can demonstrate an “exceedingly persuasive justification” that the sex-specific program is “substantially related to the achievement of an important health-related or scientific objective.”[33]

Some commenters expressed concerns that Covered Entities would not be able to revise their health insurance coverages and other offerings by July 18, 2016. OCR refused to delay the implementation of the Final Rule, but to the extent the rule requires changes to health insurance benefit design, OCR did delay implementation until the first day of the first plan year beginning on or after January 1, 2017.

Individuals with Limited English Proficiency and Auxiliary Aids and Services

The Final Rule requires Covered Entities to provide meaningful access to individuals with limited English proficiency.[34] In evaluating compliance with this requirement, the Final Rule requires the Director of the OCR to “evaluate, and give substantial weight to, the nature and importance of the health program or activity and the particular communication at issue to the individual with limited English proficiency.” The Final Rule further requires that the Director “take into account all other relevant factors, including whether the entity has developed and implemented an effective language access plan, appropriate to its particular circumstances.” The specific list of illustrative factors for the Director to consider that was set out in the Proposed Rule is no longer included in the Final Rule.

Covered Entities may need to provide oral language assistance, written translation of documents and websites, and taglines. Language assistance services required must be provided free of charge to individuals with limited English proficiency. These services must also be accurate and timely and protect the individual’s privacy and independence. OCR noted that the definition of “timely” would depend on the circumstances of each situation. Further, OCR would consider the costs of language assistance services and the resources available to the Covered Entity—including the Covered Entity’s ability to leverage resources among its partners—in evaluating whether the requirements of the Final Rule are met.

Even though the Final Rule does not list specific, mandatory methods for providing language assistance, it does contain some important prohibitions. A Covered Entity cannot require an individual to provide his or her own interpreter. The Final Rule also prohibits a Covered Entity from relying on a family member or a minor child to provide translation services, except in an emergency, unless the individual requests that the adult interpret and such assistance is appropriate under the circumstances. Additionally, a Covered Entity cannot require an individual to accept language assistance services. The Final Rule also provides technical requirements for the use of remote video interpretation services.

The Final Rule requires that individuals with disabilities be provided with auxiliary aids and services, including alternative written formats, such as Braille, and sign-language interpreters.

While Section 92.8 of the Final Rule contains an extensive notice required for Covered Entities, OCR modified that section to now only require Covered Entities to post a shorter nondiscrimination statement, along with a limited number of taglines, in significant communications that are small-sized. OCR is translating a sample nondiscrimination statement that Covered Entities can use.

Enforcement

The Final Rule states that OCR will apply existing enforcement mechanisms available under Title VI, Title IX, Section 504, and the Age Discrimination Act of 1975 for purposes of Section 1557 enforcement. Further, compensatory damages for violations of Section 1557 will be available in appropriate administrative and judicial actions brought under the Final Rule.

For recipients of federal financial assistance and State-Based Marketplaces, if such an entity fails to provide OCR with requested information in a timely, complete, and accurate manner, OCR may find noncompliance with Section 1557 and initiate appropriate enforcement procedures, including beginning the process for fund suspension or termination and taking other action authorized by law. Further, an individual or entity may bring a civil action to challenge a violation of Section 1557 in a U.S. district court in which the recipient or State-Based Marketplace is found or transacts business.

For health programs or activities administered by HHS, including the Federally Facilitated Marketplaces, the procedural provisions applicable to Section 504 apply to complaints and compliance reviews concerning discrimination on the basis of race, color, national origin, sex, age, or disability for such health programs and activities. The Final Rule also allows OCR to obtain all of the relevant information needed to investigate a complaint or determine compliance in a particular health program or activity administered by HHS. Further, HHS is prohibited from retaliating against any individual for the purpose of interfering with any right or privilege under Section 1557.[35]

Considerations for Implementation of the Final Rule

The intent of the Final Rule is to provide consumers and Covered Entities with a set of standards that will help them understand and comply with the requirements of Section 1557. The determination of whether a certain practice is discriminatory typically requires a nuanced analysis that is fact-dependent; therefore, it is not possible to identify all issues and circumstances that may raise compliance concerns. HHS advises that Covered Entities should keep in mind the purposes of the ACA and Section 1557—to expand access to care and coverage and eliminate barriers to access—when interpreting requirements of the Final Rule.

In general, Covered Entities have been subject to preexisting requirements in federal civil rights laws related to the prohibition of race, color, national origin, age, or disability discrimination for years. The prohibition of sex discrimination, however, is new for many Covered Entities and will likely require changes in action and behavior to comply with this new prohibition. Further, Covered Entities should consider whether they will provide training to the appropriate staff and incorporate the requirements of the Final Rule into their existing non-discrimination policies and procedures.

*  *  *

This Client Alert was authored by Helaine I. Fingold, Lesley R. Yeung, and Jonathan K. Hoerner. For additional information about the issues discussed in this Client Alert, please contact one of the authors or the Epstein Becker Green attorney who regularly handles your legal matters.


ENDNOTES

 

[1] 81 Fed. Reg. 31,375 (May 18, 2016), available at https://www.gpo.gov/fdsys/pkg/FR-2016-05-18/pdf/2016-11458.pdf.

[2] An issuer participating in a Health Insurance Marketplace is receiving federal financial assistance, but a health care provider that contracts with such an issuer does not become a recipient of federal financial assistance by virtue of the contract. Similarly, physicians who contract to provide health services to hospitals or clinics that receive federal financial assistance do not become a recipient of federal financial assistance by virtue of the contract. However, many health care providers are expected to be subject to Section 1557 due to federal financial assistance that they receive in their own right.

[3] HHS does not consider Medicare Part B payments to physicians to be federal financial assistance.

[4] The Medicare Access and CHIP Reauthorization Act sunsets the “meaningful use” payment adjustments for Medicare physicians after 2018.

[5] 45 C.F.R. § 92.4 (effective July 18, 2016).

[6] See 45 C.F.R. § 92.208 (effective July 18, 2016).

[7] 42 U.S.C. 2000d et seq.

[8] 20 U.S.C. 1681 et seq.

[9] 42 U.S.C. 6101 et seq.

[10] 29 U.S.C. 794.

[11] 45 C.F.R. § 92.2 (effective July 18, 2016).

[12] 45 C.F.R. § 92.101(b)(iv) (effective July 18, 2016).

[13] See 45 C.F.R. §§ 92.201-209 (effective July 18, 2016).

[14] 45 C.F.R. § 92.5 (effective July 18, 2016).

[15] 45 C.F.R. § 92.7(a) (effective July 18, 2016).

[16] 45 C.F.R. § 92.7(b) (effective July 18, 2016).

[17] 81 Fed. Reg. at 31,473.

[18] 45 C.F.R. § 92.8(a) (effective July 18, 2016).

[19] 81 Fed. Reg. at 31,472.

[20] 45 C.F.R. § 92.8(d) (effective July 18, 2016).

[21] 81 Fed. Reg. at 31,473.

[22] OCR, Translated Resources for Covered Entities, available at http://www.hhs.gov/civil-rights/for-individuals/section-1557/translated-resources/index.html.

[23] 45 C.F.R. § 92.6(a) (effective July 18, 2016).

[24] 45 C.F.R. § 92.6(b) (effective July 18, 2016).

[25] 45 C.F.R. § 92.206 (effective July 18, 2016).

[26] See Epstein Becker Green Client Alert “HHS Releases Far-Reaching Proposed Rule to Prohibit Discrimination by ‘Covered Entities’ Pursuant to Section 1557 of the Affordable Care Act” (Oct. 14, 2015), available at https://www.ebglaw.com/news/hhs-releases-far-reaching-proposed-rule-to-prohibit-discrimination-by-%E2%80%9Ccovered-entities%E2%80%9D-pursuant-to-section-1557-of-the-affordable-care-act/.

[27] 45 C.F.R. § 92.40 (effective July 18, 2016).

[28] 490 U.S. 228 (1989).

[29] 81 Fed. Reg. at 31,390.

[30] 45 C.F.R. § 92.206 (effective July 18, 2016).

[31] 81 Fed. Reg. at 31,434.

[32] Id.

[33] 81 Fed. Reg. at 31,470.

[34] 45 C.F.R. § 92.201 (effective July 18, 2016).

[35] See 45 C.F.R. §§ 92.301-303 (effective July 18, 2016).

Sessions Admits Feds Can’t Effectively Police Marijuana In States

Sessions Admits Feds Can’t Effectively Police Marijuana In States

www.marijuanamoment.net/sessions-admits-feds-cant-effectively-police-marijuana-in-states/

U.S. Attorney General Jeff Sessions acknowledged on Saturday that the Department of Justice does not have enough resources to enforce prohibition against everyone who violates federal marijuana laws.

“We’re not going to be able, even if we desired, to take over state enforcement of routine cases that might occur,” he said, referring to the growing number of states that have legalized cannabis. “Federal agents are highly paid, highly trained, and they work on cases involving cartels, international organizations, major distribution networks, large amounts of cash. And they deal with criminal organizations, RICO-type cases. And we’re not out there prosecuting those cases every day.”

Nonetheless, the attorney general made clear he believes that DEA agents should be able to enforce federal marijuana laws against anyone who violates them, regardless of state law.

“The law of the United States of America, in case you haven’t heard, applies in every state in the United States,” he said. “And I am not going to tell Colorado or California or someone else that possession of marijuana is legal under United States law.”

Sessions also took a swipe at the medical use of cannabis that is now legal in more than half the states.

“I don’t think it’s healthy, either,” he said. “If I were sick I wouldn’t suggest you take marijuana to cure yourself. I’m not sure it’s proven to be particularly helpful.”

In January, Sessions rescinded an Obama-era memo that generally allowed states to enact their own laws on marijuana without federal interference.

Sessions Rescinds Memo On State Marijuana Laws

“I believe it’s a rule of law question,” Sessions said on Saturday, arguing that the interpretation of the now-defunct Obama policy was “incorrect legally.”

Sessions’s new remarks, which he made in response to an audience question at a Federalist Society event at Georgetown University Law Center, were first reported by the Associated Press.

Going forward, the attorney general said, the feds would be focused not on “small marijuana cases,” but instead on “criminal enterprise” that is “being done on federal lands and parklands and doing destruction to our park system.”

Such activity was designated as that which could trigger enforcement actions under the earlier Obama guidance as well.

The big unanswered question remains to what extend federal law enforcement and prosecutors in Sessions’s department will seek to go after state-licensed marijuana growers, processors and sellers that operate in accordance with local policies.

Trump officials study death penalty for drug dealers in opioid epidemic

www.bangordailynews.com/2018/03/10/news/nation/trump-officials-study-death-penalty-for-drug-dealers-in-opioid-epidemic/

WASHINGTON – The Trump administration is studying new policy that could allow prosecutors to seek the death penalty for drug dealers, according to people with knowledge of the discussions, a sign that the White House wants to make a strong statement in addressing the opioid crisis.

President Donald Trump last week suggested executing drug dealers as a way to make a dent in opioid addiction. Opioids killed nearly 64,000 people in 2016, and the crisis is straining local health and emergency services.

People familiar with the discussions said that the president’s Domestic Policy Council and the Department of Justice are studying potential policy changes and that a final announcement could come within weeks. The White House has said one approach it might take is to make trafficking large quantities of fentanyl – a powerful synthetic opioid – a capital crime because even small amounts of the drug can be fatal. White House officials also are studying tougher noncapital penalties for large-scale dealers.

Trump said last week that the administration would soon roll out unspecified “strong” policies on opioids. White House officials said Trump has privately expressed interest in Singapore’s policy of executing drug dealers.

“Some countries have a very tough penalty, the ultimate penalty, and they have much less of a drug problem than we do,” Trump said during an appearance at a White House summit on opioids last week.

Trump also has endorsed Philippine President Rodrigo Duterte’s approach to the issue; Duterte’s “drug war” has led to the deaths of thousands of people by extrajudicial police killings. Last year, Trump praised Duterte in a phone call for doing an “unbelievable job on the drug problem,” according to the New York Times.

Kellyanne Conway, counselor to the president, is leading much of the work on opioids for the White House. Singaporean representatives have briefed senior White House officials on their country’s drug policies, which include treatment and education, but also the death penalty, and they provided a PowerPoint presentation on that country’s laws.

Singapore’s model is more in line with the administration’s goals for drug policy than some other countries, a senior administration official said.

“That is seen as the holistic approach that approximates what this White House is trying to do,” a senior administration official said.

The Department of Justice declined to comment on the policy discussion. A White House spokesman did not respond to a request for comment Friday.

Federal law currently allows for the death penalty to be applied in four types of drug-related cases, according to the Death Penalty Information Center: murder committed during a drug-related drive-by shooting, murder committed with the use of a firearm during a drug trafficking crime, murder related to drug trafficking and the death of a law enforcement officer that relates to drugs.

Peter Meyers, a professor at the George Washington University School of Law, said he doesn’t agree with the idea of adding more capital crimes for drug dealers, but he said it could be a legal approach: “It very likely would be constitutional if they want to do it.”

The administration’s directives come as prosecutors nationwide are cracking down on higher-level drug dealers and law enforcement officials are looking at increased penalties for fentanyl trafficking and dealing. But at the same time, public health officials – including those in the Trump administration – and many in law enforcement are emphasizing treatment rather than punitive measures for low-level users and those addicted to drugs.

Attorney General Jeff Sessions has directed federal prosecutors to pursue the most severe penalties for drug offenses. The Department of Justice said last year it will aggressively prosecute traffickers of any fentanyl-related substance.

Some argue executing drug dealers could have a raft of unintended consequences, such as deterring people from calling police when they know someone is overdosing.

 While news of capital charges against a drug dealer would spread quickly and possibly be a deterrent, said Daniel Ciccarone, a professor of family and community medicine at the University of California at San Francisco, it could also drive drug users underground.

“It will keep people from any positive interface with police, any positive interface with public health, any interface with doctors,” he said, noting that it could lead to fewer people receiving treatment for their addictions. “People will become afraid and hide. They won’t trust the police, and they won’t trust the doctor either.”

Ciccarone said there is also concern that the laws could ensnare low-level drug dealers, many of whom do not know that their products contain lethal amounts of opioids and some of whom are battling addiction.

“We’re not talking El Chapo-level people,” he said, referring to Joaquín “El Chapo” Guzmán, the former leader of the Sinaloa cartel who was extradited to the United States last year. U.S. officials had to assure their Mexican counterparts that Guzmán would not face the death penalty as part of extradition negotiations.

“The closer you get to the ground, the closer you get to people who are easy to capture and the more unknown the fentanyl issue is,” Ciccarone said. “I don’t believe that expanding the drug penalty further for other trafficking offenses is going to solve the opioid epidemic,” she said.

Regina LaBelle, deputy chief of staff at the Office of National Drug Control Policy in the Obama administration, said that current laws that allow for drug dealers to be charged with a capital offense haven’t had a deterrent effect.

If this comes to be law/policy… could the DEA apply this to prescribers that the DEA have determined to be running “pill mills” and any prescriber that had a pt died from a drug overdose… be subject to a death penalty ?  What would that do to the chronic pain community and/or all those people dealing with subjective disease and have a valid medical necessity for a controlled substance and being able to get their necessary medication ?

Should AG Session appoint special prosecutor to investigate the DEA ?

DEA Praises Man Who Once Said Marijuana “Makes Darkies Think They’re as Good as White Men”

www.thejointblog.com/dea-praises-man-said-marijuana-makes-darkies-think-theyre-good-white-men/

The Drug Enforcement Administration (DEA) has Tweeted praise towards an unabashed racist who helped make marijuana illegal.

No one is more responsible for marijuana  prohibition than Harry J. Anslinger, a former government official who used racism to make the point that marijuana use should be a crime. When arguing for prohibition, Anslinger made statements such as “reefer makes darkies think they’re as good as white men“, and “marijuana causes white women to seek sexual relations with Negroes”.

Despite this disgusting and blatant racism, the DEA sent out a Tweet yesterday praising the man.

“Harry Anslinger helped bring drug law enforcement into the modern age”, says the Tweet made a little after noon. “He served as head of US drug enforcement for 5 presidents from to , retiring in 1962. They end the Tweet with the hashtags “#TBT” and “#ThrowbackThursday”.

Response to the Tweet has shown almost unanimous opposition to it.

“Not one single positive response to this tweet”, responded Harold Carr. “Perhaps y’all should read them and reflect on how this monster is viewed by most sane people.”

The Tweet, and its responses, can be found by clicking here.

 

 

Insurers and other nontraditional care providers like CVS say they aren’t trying to replace doctors or randomly shave expenses.

Insurers get into care, but is it good for your health?

www.wtop.com/national/2018/03/insurers-get-into-care-but-is-it-good-for-your-health/

In the not-too-distant future, your health insurance, your prescription drugs and some of your treatment may come from the same company.

Insurers are dropping billions of dollars on acquisitions and expansions in order to get more involved in customer health. They say this push can help cut costs and improve care, in part by keeping the sickest patients healthy and out of expensive hospitals.

That’s a huge potential benefit for employers and other customers stressed by rising costs. But is this good for your health?

 That question worries some health care insiders who wonder if the patient’s best interest — and not profits — will remain the focus as insurers dive deeper into care.

“The fights about price and cost are only going to get worse. Now you’ve got more integrated and powerful private insurers … coming up with the answer,” said medical ethicist Arthur Caplan.

The insurer Cigna said Thursday it will spend $52 billion to buy Express Scripts, which administers prescription benefits for about 80 million people.

Late last year, CVS Health also announced a roughly $69 billion deal to buy another insurer, Aetna. Those companies plan to convert drugstores into health care hotspots that people can turn to for a variety of needs in between doctor visits.

Other insurance companies, including Humana and UnitedHealth Group, also are making deals to expand their role in managing or providing care

The concept isn’t new. Many people already have coverage through health maintenance organizations, or HMOs, where insurers either employ doctors or contract with them to manage care.

But major insurers are buying into the idea because the usual ways they control costs — by negotiating rates with hospitals or cutting their own expenses — have a limited impact, said Standard & Poor’s analyst Deep Banerjee. He added that delving into care is the most efficient way for insurers to manage costs.

If insurers don’t find a better way to control costs, Amazon might. The online giant announced earlier this year that it will collaborate with billionaire Warren Buffett and JPMorgan Chase to create a company aimed at giving employees high-quality, affordable care. The companies have yet to announce details.

Insurers and other nontraditional care providers like CVS say they aren’t trying to replace doctors or randomly shave expenses.

They say the goal is to supplement the care a patient already receives or provide affordable options for people who don’t have doctors. Big acquisitions also help them gather more information about customers, which can improve care, for instance, by helping doctors figure out which medicine might work best for a patient.

They also say that cutting costs and improving care are not mutually exclusive goals.

Humana gives wireless scales to about 2,000 patients with congestive heart failure — a sliver of the insurer’s total enrollment — and has nurses monitor their weight remotely. A sudden gain can be a sign of looming trouble for these patients, so a nurse may check in to see if they need to adjust their prescription or see a doctor.

“If we can intercede before a heart attack, we not only obviously help the individual, but we prevent an ER visit and downstream cost of that,” CEO Bruce Broussard said earlier this year at a health care conference.

UnitedHealth Group runs the nation’s largest insurer, but its separate Optum business also operates more than 1,100 doctor offices, urgent care and surgery centers.

Optum leaders say their urgent centers can handle 90 percent of the care patients would receive in an emergency room at a fraction of the cost, thanks to lower overhead and fewer staff. Their surgery centers can perform outpatient procedures, which don’t involve an overnight stay, for about half of what a hospital charges and still deliver high quality care, they say.

“It’s about more care in the right setting,” Optum executive Andrew Hayek said, adding that his company works with more than 80 different health plans, not just UnitedHealth customers.

Insurers say the expansions will lead to more personalized, affordable health care. Whether the average patient sees lighter insurance or pharmacy bills remains to be seen.

Health care consultant Bob Laszewski expects insurers to be focused first on making sure their stockholders get a return from these big deals

“When you spend $50 billion of shareholder money, it’s clear the accountability is going to be with the shareholder not with the patient,” the former insurance executive said.

Lawmakers and doctors have long been concerned about corporate influences on medical care. Most states have laws or standards that prevent a business or employer from interfering with a doctor’s medical judgment, health care attorney Kim Harvey Looney said. But these standards don’t prevent an insurer from denying coverage if a treatment is deemed experimental or excluded under a plan.

That worries Caplan, an ethicist with New York University’s School of Medicine. He wonders how hard doctors will fight for patients if it means clashing with their own employers.

“It’s a little easier to be an advocate for the patient when you don’t work for the corporation that is controlling the reimbursement decision,” he said.

Another medical ethicist, Dr. Matt DeCamp of Johns Hopkins University, said he doesn’t see an inherent conflict of interest when insurers provide care.

Whether one surfaces depends on how the deals are structured. DeCamp would want to know how involved the patient’s regular doctor is with insurer programs that manage care and whether participation is linked to the cost of coverage. That could make it hard for patients to say no.

Ultimately, insurers can earn customer trust simply by keeping them healthy for a reasonable price, said health economist Paul Keckley. But that will be a struggle for an industry in which the average patient already has little faith, he said.

“You trust your nurses most, your doctors and pharmacists next, hospitals some, and insurers none,” he said.

The people that I know – mostly that use to work for CVS – claims that CVS will not “shave random expenses” …they will take a CHAINSAW to all expenses.

All of these corporations that are merging… are interested in on thing MORE PROFITS and they will attempt to get to that point by dictating what care people can have and what healthcare providers that pts can use.

 

Acetaminophen: 112,000 annual calls to poison control centers, 59,000 emergency room visits and 38,000 hospitalizations

Acetaminophen Often Taken In Excess During Cold and Flu Season

https://www.acsh.org/news/2018/03/09/acetaminophen-often-taken-excess-during-cold-and-flu-season-12682

A new study published in the British Journal of Clinical Pharmacology suggests increased use and overdose of the common over-the-counter (OTC) pain reliever and fever reducing medication, acetaminophen, happens during cold and flu season. No surprise there. People don’t often realize that there are multiple medicines in OTC cold and cough remedies and they routinely take a few different ones when sick, thereby ingesting excessive amounts as many contain it as an active ingredient.

These findings are in line with a disturbing trend of medication errors being on the rise outside of healthcare facilities – many resulting in serious outcomes and most frequently occurring at home. Though the design of this recent research leaves much to be desired given it involved online self-reporting as well as survey collection among other limitations, it follows a known pattern of noncompliance whether discussing drugs on the pharmacy store shelves or those obtained via prescription.

Since, according to the authors, the overuse of acetaminophen is responsible for 112,000 annual calls to poison control centers, 59,000 emergency room visits and 38,000 hospitalizations, clarifying confusion is certainly worth the effort to help diminish the healthcare burden. 

Fortunately, this study’s glimpse into improper acetaminophen self-administration didn’t yield severe consequences like known liver damage given participants didn’t substantially exceed maximum daily recommendations or on a majority of usage days. But, this is where it is important to recognize that this is a very dangerous drug when taken at supratherapeutic levels. Lately, the standard of care is to err on the lower side of dosing since we see liver toxicity at not as high a level as previously thought. Acetaminophen is the perfect example of how an OTC drug can pose greater risk in high quantities than another medication might that is prescription. Taken in an appropriate dose it can be helpful and safe. But, go overboard through combining drugs to exceed recommended guidelines and/or add alcohol and other toxic substances and the damage can be signficant.

There are a variety of factors that influence improper medication use. For one, during an acute illness like flu or other respiratory infections, polypharmacy can be problematic coupled with sleep deprivation, several family members sick in a household or more than one caregiver, to name a few.

Then, there are the issues in the realm of chronic disease. According to a recent study that tracked unintentional therapeutic pharmaceutical errors and focused on those causing profound impairment, disability and death, there was a 100% rate increase from 2000 to 2012. All age groups reflected such an increase, except those under six years of age (likely explained by the FDA’s 2007 restriction of cold and cough suppressant sales to children under six due to their lack of proven efficacy and their ability to do harm). See Serious Medication Mistakes Happening At Home—The Why Depends On The Who.

Many solutions attempting to make a dent in the issue are already in play, like containers that alarm if a person misses a dose. The FDA just approved the first pill with an ingestible tracking sensor. Though there are concerns over whether this is too invasive and imperils patient privacy, the technology is quite innovative. To learn more, read FDA Approves Pill With Tracking Sensor: Ingenious or Big Brother?

The take home message with respect to this acetaminophen publication is that possible seasonal variability in usage could help best target more informed and educational public health messaging. Despite the work’s restrictions, it helps reinforce that there is still room to improve compliance and a focus should be on spreading awareness about the hazards of combining medicines. In appropriate doses, modern medicine can often miraculously assuage suffering and promote cures. Step outside the therapeutic window and the range of adverse outcomes can shift from minor to fatal, after all it is the dose that makes the poison.

ACLU sues US, alleging systematic separation of parents and children

http://www.foxnews.com/us/2018/03/09/aclu-sues-us-alleging-systematic-separation-parents-and-children.html

The American Civil Liberties Union has filed a class-action lawsuit accusing the U.S. government of broadly separating immigrant families seeking asylum.

The lawsuit, filed Friday, follows action the ACLU took in the case of a Congolese woman and her 7-year-old daughter, who were being held in immigration facilities 2,000 miles apart.

The woman was released Tuesday from a San Diego detention center. The 7-year-old remains at a Chicago facility for unaccompanied immigrant children.

Immigrant advocates accuse the Trump administration of systematically separating parents and children seeking asylum to deter people from coming to the United States.

Administration officials acknowledge they have separated some families but say they do not have a broad policy to do so.

 

 

https://www.aclu.org/about/aclu-history

The ACLU also remains a champion of segments of the population who have traditionally been denied their rights, with much of our work today focused on equality for people of color, women, gay and transgender people, prisoners, immigrants, and people with disabilities.